Targeted Medical Pharma, Inc.
TRGM
$0.00
$0.000.00%
| Weiss Ratings | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.41 | |||
| Price History | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -99.00% | |||
| 60-Day Total Return | -99.00% | |||
| 90-Day Total Return | -99.00% | |||
| Year to Date Total Return | -99.00% | |||
| 1-Year Total Return | -99.00% | |||
| 2-Year Total Return | -99.00% | |||
| 3-Year Total Return | -99.50% | |||
| 5-Year Total Return | -99.99% | |||
| 52-Week High % Change | -99.00% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Feb 25, 2025 | |||
| 52-Week High Price (Date) | Feb 24, 2025 | |||
| Valuation | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 29.00 | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -- | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -- | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | -- | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 310-474-9809 | |||
| Address | 2980 Beverly Glen Circle Los Angeles, CA 90077 | |||
| Website | -- | |||
| Country | United States | |||
| Year Founded | 1996 | |||
| Profitability | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -35.93% | |||
| Profit Margin | -57.85% | |||
| Management Effectiveness | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -47.96% | |||
| Return on Equity | -- | |||
| Income Statement | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 5.26M | |||
| Total Revenue (TTM) | 5.26M | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | 3.17M | |||
| EBITDA (TTM) | -1.66M | |||
| EBIT (TTM) | -1.89M | |||
| Net Income (TTM) | -3.04M | |||
| Net Income Avl. to Common (TTM) | -3.04M | |||
| Total Revenue Growth (Q YOY) | -9.00% | |||
| Earnings Growth (Q YOY) | 59.22% | |||
| EPS Diluted (TTM) | -0.11 | |||
| EPS Diluted Growth (Q YOY) | 62.23% | |||
| Balance Sheet | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 82.60K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 833.00K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -12.92M | |||
| Current Ratio (Q) | 0.057 | |||
| Book Value Per Share (Q) | -- | |||
| Total Assets (Q) | -- | |||
| Total Current Liabilities (Q) | 14.68M | |||
| Total Debt (Q) | -- | |||
| Total Liabilities (Q) | -- | |||
| Total Common Equity (Q) | -12.90M | |||
| Cash Flow | TRGM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 0.00 | |||
| Cash from Financing (TTM) | 1.35M | |||
| Net Change in Cash (TTM) | 70.80K | |||
| Levered Free Cash Flow (TTM) | -209.30K | |||
| Cash from Operations (TTM) | -1.28M | |||
